Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis

This post hoc exploratory analysis found no clear associations between frequently used concomitant medication combinations and disease progression in 1450 patients with IPF enrolled in phase III trials, but several combinations may require further study. http://bit.ly/2ZzyMXR

Detalles Bibliográficos
Autores principales: Kreuter, Michael, Lederer, David J., Cottin, Vincent, Kahn, Nicolas, Ley, Brett, Vancheri, Carlo, Weycker, Derek, Atwood, Mark, Kirchgaessler, Klaus-Uwe, Ryerson, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906546/
https://www.ncbi.nlm.nih.gov/pubmed/31537696
http://dx.doi.org/10.1183/13993003.01188-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906546/
https://www.ncbi.nlm.nih.gov/pubmed/31537696
http://dx.doi.org/10.1183/13993003.01188-2019

Ejemplares similares